Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR § 807.93

Submitter

Implant Innovations, Inc.

4555 Riverside

Palm Beach Gardens, FL 33410

Contact

Jacquelyn A. Hughes, RAC

Director, Regulatory Affairs and Quality Assurance

Implant Innovations, Inc.

4555 Riverside

Palm Beach Gardens, FL 33410

Tel. 561-776-6819 Fax. 561-776-6852

Email jhughes@3implant.com

Date Prepared

May 8, 2003

Device Name

OSSEOTITE NTTM CERTAINTM Implants

Classification Name

Endosseous Dental Implant

Device

Class III

Classification

Dental Devices Panel

21 CFR § 872.3640

Predicate Devices K014235 - OSSEOTITE NT™ Dental Implants

K972444 - 3i Innovative Implants and Cover Screws K935544 - Threaded Self-Tapping Threaded Implants

K980549 – OSSEOTITE Dental Implants K983347 - OSSEOTITE Dental Implants

K022009 - 3i Dental Implants

Performance

Performance standards have not been established by the

FDA under Section 514 of the Federal Food, Drug and

Cosmetic Act.

Device Description

The OSSEOTITE NT Certain Implants are internally connected, tapered implants designed to mimic the shape

and form of a natural tooth.

Indications for

Use

The OSSEOTITE NT Certain Implants are

indicated for surgical placement in the upper or lower jaw to provide a means for prosthetic attachment to restore a

patient's chewing function.

Technological Characteristics The OSSEOTITE NT Certain Implants contain

features and functions which are similar to the currently available OSSEOTITE NT^{TM} Implants and 3i Innovative

Implants and Cover Screws.

Conclusion

The OSSEOTITE NT Certain Implants are substantially equivalent to the legally marketed OSSEOTITE NTImplants and 3i Innovative Implants and Cover Screws.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 8 2003

Ms. Jacquelyn A. Hughes Director, Regulatory Affairs Quality Assurance 4555 Riverside Drive Palm Beach Gardens, Florida 33410

Re: K031475

Trade/Device Name: Osseotite NTTM CertanTM Implants

Regulation Number: 872.3640

Regulation Name: Endosseous Implant

Regulatory Class: III Product Code: DZE Dated: May 8, 2003 Received: May 9, 2003

Dear Ms. Hughes

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Susan Runner, DDS, MA

Interim Director

Division of Anesthesiology, General Hospital Infection Control and Dental Devices

Fatures Crusite/for

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

			Page <u>1</u> of <u>1</u>
510(k) Number (if know	vn): <u>K0314</u> 7.	5	
Device Name: OSSEOT	ITE NT™ CERTA	IN TM Implants	
ndications for Use:			
<i>i</i> dental implants are interpreted in the dental implants are interpreted in the dental interpr			
(PLEASE DO NOT V			NUE ON ANOTHER
		NEEDED)	evice Evaluation (ODE)
ı	Concurrence of	CDKII, Office of De	evice Evaluation (ODE)
	Ma Con	My for MSR	
	(Division Sign-Off) Division of Anesther Infection Control, De	siology, General Hospi ental Devices	tal,
	510(k) Number:	K031475	<u> </u>
	/		·
Prescription Use: V Per 21 CFR 801.109)	OR	Over the Cou	unter Use: